Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-12-07
2004-01-27
Nolan, Patrick J. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009100
Reexamination Certificate
active
06682902
ABSTRACT:
FIELD OF THE INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; methods of making the polynucleotides and polypeptides, and their variants and derivatives; antibodies directed toward the polypeptides, their variants and derivatives; and uses of the polynucleotides, polypeptides, variants, derivatives and antibodies. In particular, in these and in other regards, the invention relates to novel human extracellular matrix polypeptides (designated RG1), polynucleotides which encode these polypeptides, antibodies directed toward these polypeptides, and antisense polynucleotides that block RG1 expression.
BACKGROUND OF THE INVENTION
Prostate cancer is a frequently occurring disease in man, in that it is found in about one third of men over the age of 45. There is evidence for both genetic and environmental causes, with the majority of cases probably being the result of a combination of both factors. Studies of familial cancer have suggested that genetic predisposition plays a role in about 5-10% of all prostate cancers, and in about 45% of cases in men younger than 55.
There is evidence that prostate cancer develops as a multi-step disease, with one of the precursor lesions being prostatic intraepithelial neoplasia (PIN). Early stages of the disease are androgen dependent, while later stages are hormone independent. A proliferative disorder of the prostate known as benign prostatic hyperplasia is often detected clinically but is probably not a stage in the development of cancer. It is, however, frequently associated with prostate cancer. Cancers in the prostate are often multifocal, generally slow growing, and heterogeneous. Late stage cancers frequently metastasize to the lymph nodes and to the bone.
Prostate cancer is usually diagnosed by physical examination and by serum levels of prostate specific antigen (PSA). Radical prostatectomy is the treatment of choice for localized disease. Advanced metastatic disease is treated currently by androgen ablation induced by orchiectomy or treatment with GnRH (gonadotrophin releasing hormone), and by anti-androgen therapy. However, advanced disease almost invariably becomes hormone resistant and there is no cure for progressive disease. Moreover, there are serious side effects associated with both radical prostatectomy and androgen ablation therapy. These include a high risk of incontinence and impotence associated with radical prostatectomy and bone fractures and osteoporosis associated with androgen ablation therapy.
There is, therefore, a considerable need for new therapeutic approaches for both early and late stage prostate cancer. There is also a significant need for new diagnostic agents, in particular agents that can discriminate stages of the disease, as this significantly influences the treatment options. For example, if disease has progressed beyond the prostate and has metastasized to the lymph nodes, radical prostatectomy is not undertaken as it has no effect on progression, but may have significant unwanted side effects. An agent that could detect metastasis, in vivo, would have considerable value.
Changes in the expression of specific proteins have been demonstrated in prostate cancer including abnormal p53 expression in late stage prostate cancer, reduced levels of TGF-&bgr; receptors, reduced levels of E-cadherin, C-Cam (a cell adhesion molecule), and several integrins. The expression of the oncogene bcl-2 is strikingly elevated in late stage androgen independent tumors, and prognosis for patients expression bcl-2 at elevated levels is relatively poor. While the previously mentioned changes in gene expression are well documented, no changes in expression have been identified that have been demonstrated to be causative for the disease. It would, therefore, be useful to identify new proteins whose expression is linked to the presence or development of prostate tumors which could serve as molecular targets for prostate cancer diagnosis and therapy.
This invention discloses a new homologue to a superfamily of extracellular matrix proteins. This homologue, named RG1 is expressed in prostate tissue and may be over-expressed in prostate tumors.
The extracellular matrix is a complex meshwork of collagen and elastin, embedded in a viscoelastic ground substance composed of proteoglycans and glycoproteins. The matrix exists as a three dimensional supporting scaffold that isolates tissue compartments, mediates cell attachment and determines tissue architecture (Bissel et al.,
J. Theor. Biol.
99:31-68, 1982; Carlson et al.,
Proc. Natl. Acad. Sci. USA
78:2403-2406, 1981). The matrix acts as a macromolecular filter (Hay, E. D.,
Cell Biology of Extracellular Matrix,
New York, Plenum Press, 1982) and also influences cytodifferentiation, mitogenesis, and morphogenesis (Gospodarowiczs, D.,
Cancer Res.
38:4155-171, 1978). The biochemical interactions between normal cells and the matrix may be altered in neoplasia, and this may influence tumor proliferation. Tumor cells can interact with the matrix in different ways. First, tumor cells can attach to the matrix via specific plasma membrane receptors (Terranova et al.,
Cancer Res.
42:2265-2269, 1982). Second, degradation of the matrix is mediated by a cascade of enzymes that are contributed by the tumor cell and the host (Eisen et al.,
Bioch. Biophys. Acta
151:637-645, 1968). Third, in differentiated areas of the tumor, tumor cells may synthesize and accumulate matrix or induce the host cell to accumulate excessive matrix (Brownstein et al.,
Cancer
40: 2979-2986, 1977).
RG1 shows homology to a superfamily of extracellular matrix proteins, encoded by the Mindin/F-spondin genes. The gene family is united by two conserved spondin domains, FS1 and FS2, near the amino terminus and at least one thrombospondin type 1 repeat (TSR1) at the carboxy terminus (Shimeld, S. M.,
Mol. Biol. Evol.
15(9): 1218-1223, 1998). The TSR motif was originally found in the vertebrate extracellular matrix proteins (Bornstein, P.,
J. Cell Biol.
130:503-506, 1995) and has subsequently been found in several other extracellular matrix proteins. There are several lines of evidence that TSR's mediate cell adhesion and play a key role in tumorigenesis. For example, it has been demonstrated that proteolytic fragments of thrombospondin that contain the TSR's, and synthetic peptides having sequences corresponding to the TSR region of thrombospondin, promote tumor cell adhesion and metastasis (Prater et al.,
J. Cell Biol.
112:1031-1040, 1991; Tuszynski and Nicosia,
BioEssays
18:71-76, 1996), have anti-angiogenic activity (Tolsma et al.,
J. Cell Biol.
122:497-511, 1993) and inhibit platelet aggregation and melanoma metastasis (Tuszynski et al.,
J. Cell Biol.
116:209-217, 1992).
Currently, the members of this superfamily include a gene in
Caenorhabditis elegans,
a single gene in Drosophila and multiple genes in vertebrates. In
C. elegans,
the gene F10E7.4 encodes for five TSR's in addition to the FS1 and FS2 domains (Higashijima et.al.,
Dev. Biol.
192:211-227, 1997). In Drosophila, the family member termed M-spondin (mspo) contains the FS1 and FS2 domains and a single TSR (Umemiya et al.,
Dev. Biol.
186:165-176, 1997). The M-spondin gene encodes a secreted protein that is localized at the muscle attachment sites and seems to function as an extracellular matrix protein that supports muscle—apodeme attachment. The family members in vertebrates include genes isolated from zebrafish (Mindin1 and Mindin2, F-spondin1, and F-spondin2), rat F-spondin, Xenopus F-spondin and rat Mindin. Mindin1 and Mindin2 are closely related to each other and have a gene structure similar to that of Drosophila M-spondin. Both Mindin1 and Mindin2 genes encode for a single TSR in addition to the FS1 and FS2 domains (Higashijima et.al.,
Dev. Biol.
192:211-227, 1997). Zebrafish F-spondinl and F-spondin2, rat F-spondin (Klar et al.,
Cell
69:95-110, 1992) and Xenopus F-spondin (Altaba et al.,
Proc. Natl. Ac
Harkins Richard
Parkes Deborah
Parry Gordon
Schneider Douglas W.
Steinbrecher Renate
Nolan Patrick J.
Schering Aktiengesellschaft
Washtien Wendy L.
LandOfFree
DNA encoding a novel RG1 polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding a novel RG1 polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding a novel RG1 polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3210975